🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke

RecruitingPhase 2Ages 18 Years - anyAllAarhus University Hospital
NCT05630586 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Can Semaglutide help reduce the damage caused by a stroke? ASSET trial is a national, multicenter, clinical trial, investigating the safety and efficacy of Semaglutide in non-diabetic patients with acute ischemic stroke. Stroke is a worldwide leading cause of long-term disability and death. In the most common type of stroke (ischemic stroke), a blood clot obstructs an artery in the brain, and thereby prevents oxygenated blood from reaching an area of the brain. Brain cells are particularly vulnerable to the lack of oxygen. In the areas most severely affected by a stroke, brain cells die after 5 minutes. As more time pass, the affected area expands, and more brain cells perish. Today, efficient treatments aiming at reestablishing the flow of blood by either breaking down the blood clot (thrombolysis) or removing the clot (thrombektomi) are used. However, a significant amount of patients

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Male and female patients (≥ 18 years) at the time of signed informed consent/proxy consent * Acute ischemic stroke with disabling neurological deficits (defined as an impairment of one or more of the following: language, motor function, cognition, gaze, vision, neglect, or ataxia) * Onset/last seen well to randomization \< 4.5 hours * None to moderate disability in daily living before symptom onset (pre-stroke modified Rankin Scale 0-3) Exclusion Criteria: * Diabetes (known) or plasma/point of care test-glucose \>11.1 mmol/L at admission * BMI\< 22 * History of pancreatitis, medullary thyroid carcinoma * Predisposition or known Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) * Short remaining life expectancy (\< 12months) and/or severe neurodegenerative disease * Pregnancy or planned pregnancy within 12 months or breastfeeding * Renal impairment measured as estimated glomerular filtration rate (eGFR) value of \<30 mL/min/1.73 m2
💊

What it tests

  • Semaglutide
  • Standard care
📍

Where

1 site
Aarhus University Hospital
Aarhus, Denmark
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy